Abstract The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington et al., 2014) . This Registered report describes the proposed replication plan of key experiments from 'A coding-independent function of gene and pseudogene mRNAs regulates tumour biology' by Poliseno et al. (2010) , published in Nature in 2010. The key experiments to be replicated are reported in Figures 1D, 2F -H, and 4A. In these experiments, Poliseno and colleagues report microRNAs miR-19b and miR-20a transcriptionally suppress both PTEN and PTENP1 in prostate cancer cells ( Figure 1D ; Poliseno et al., 2010) . Decreased expression of PTEN and/or PTENP1 resulted in downregulated PTEN protein levels ( Figure 2H ), downregulation of both mRNAs ( Figure 2G) , and increased tumor cell proliferation ( Figure 2F ; Poliseno et al., 2010) . Furthermore, overexpression of the PTEN 3′ UTR enhanced PTENP1 mRNA abundance limiting tumor cell proliferation, providing additional evidence for the co-regulation of PTEN and PTENP1 ( Figure 4A ; Poliseno et al., 2010) .
Introduction
The phosphatase and tensin homolog gene (PTEN) functions as a negative repressor of the PI3K/Akt survival pathway and is one of the most frequently deleted tumor suppressor genes in human cancer (Stambolic et al., 1998; Song et al., 2012) . As a regulator of PI3K signaling, loss of PTEN results in over-activation of Akt, leading to unchecked cell proliferation, reduced apoptosis, and elevated tumor angiogenesis (Stambolic et al., 1998; Carracedo et al., 2008) . In prostate cancer, decreases in PTEN protein expression, either by allelic deletion or functional loss caused by mutation and/or epigenetic modification, can lead to invasive prostate carcinoma (Trotman et al., 2003; Phin et al., 2013) . In preclinical systems, the genetic restoration of PTEN induces apoptosis in cancer cell lines and has a significant negative effect on tumor growth in multiple in vivo models (Li et al., 1998; Lu et al., 1999; Tian et al., 1999; Chen et al., 2011) . In contrast, clinical efforts to restore PTEN functionality have instead focused on targeting kinases in the PI3K pathway, including PI3K, Akt, and the mammalian target of rapamycin (Hopkins and Parsons, 2014) . However, the development of PI3K targeting drugs has been complicated by the limited tolerability of current pharmacological treatments as well as tumor heterogeneity (Gerlinger et al., 2012; Bauer et al., 2014) .
It is increasingly apparent that a complex regulatory network exists between the diverse RNA species pervasive in the human transcriptome. MicroRNAs (miRNAs) are small non-coding RNAs that bind to *For correspondence: tim@ cos.io complementary sequences in the 3′ untranslated regions (UTR) of target messenger RNAs (mRNA), resulting in transcriptional downregulation of the target gene (Sen et al., 2014) . Meng and colleagues showed that PTEN was repressed by miR-21, one of the most frequently upregulated miRNAs in cancer, in hepatocarcinoma cells, suggesting that the oncogenic potential of miR-21 occurs via the downregulation of PTEN expression (Chan et al., 2005; Meng et al., 2006; Volinia et al., 2006; Meng et al., 2007; Si et al., 2007) . Several miRNAs that target PTEN have since been reported (Jackson et al., 2014; Wang et al., 2015) . While miRNAs play a functional role in silencing target gene expression, it is proposed that miRNAs themselves are subject to regulation by competing endogenous RNA (ceRNA) species, including pseudogenes, long non-coding RNAs, and circular RNAs Cesana and Daley, 2013) . In plants, for example, the non-protein coding gene IPS1 sequesters miRNAs away from their mRNA targets, thereby leading to an accumulation of target transcripts (Franco-Zorrilla et al., 2007) . Poliseno and colleagues proposed that pseudogenes, which are non-coding genomic DNA sequences closely related to parental genes, can modulate parental gene expression by influencing the available levels of miRNAs within a cell (Poliseno et al., 2010; Cesana and Daley, 2013) . However, the extent and manner that ceRNAs can exert a consequential effect on the repression of targets for that miRNA is currently unclear (Broderick and Zamore, 2014) . Recently, Denzler and colleagues analyzed the stoichiometric relationship of miR-122 and target sites in adult mouse liver and reported that the natural abundance of target sites exceeded miRNAs, making the ceRNA hypothesis unlikely (Denzler et al., 2014) .
PTENP1 is a pseudogene that shares close homology with PTEN, including the ability to bind miRNAs (Fujii et al., 1999) . To determine whether PTEN and PTENP1 expression levels are modulated by miRNA activity, Poliseno and colleagues first established that the PTEN-targeting miRNAs miR-19b and miR-20a were able to target both PTEN and PTENP1 (Poliseno et al., 2010) . As reported in Figure 1D , overexpression of miR-19b and miR-20a in prostate cancer cells resulted in a significant decrease in PTEN and PTENP1 mRNA transcription. This is supported by additional studies demonstrating that overexpression of either miR-19b or miR-20a in cancer cell lines resulted in reduced PTEN mRNA levels and protein expression (Luo et al., 2013; Tian et al., 2013; Wu et al., 2014) . The ability of miR-19b and miR-20a to target PTEN in prostate cancer was further confirmed by Tay et al. (2011) . These key findings established that PTEN and PTENP1 are regulated by interactions with miRNA in multiple cancer cell types and will be replicated in Protocol 1.
In Figure 2F -H, Poliseno and colleagues tested the phenotypic consequences of PTENP1 downregulation by specifically targeting PTEN and/or PTENP1 expression. Downregulation of PTENP1 in DU145 prostate cancer cells resulted in a significant decrease in both PTEN and PTENP1 mRNA levels and protein expression (Figure 2G-H; Poliseno et al., 2010) . Furthermore, downregulation of PTENP1 profoundly accelerated the proliferation of DU145 cells ( Figure 2F ), with silencing of both PTEN and PTENP1 having an additive effect (Poliseno et al., 2010) . These experiments will be replicated in Protocols 2, 3, and 4. Recently, Tay and colleagues reported that PTEN-ceRNAs, including CNOT6L and VAPA, phenocopied PTENP1 activity, as downregulation of these non-coding transcripts in prostate and colon cancer cells were also able to modulate PTEN expression, Akt activity, and cell growth . Additionally, other PTEN-ceRNAs that regulate PTEN expression have been reported in brain, breast, and skin cancers (Lee et al., 2010; Karreth et al., 2011; Sumazin et al., 2011) . Further to this, PTENP1 antisense RNA has been reported to regulate PTEN transcription and mRNA stability, suggesting a model where the PTENP1 pseudogene has biomodal functionality modulating PTEN (Johnsson et al., 2013) .
As an extension of the findings reported in Figure 2 and further genomic analysis, Poliseno and colleagues demonstrated that the PTEN 3′ UTR regulates pseudogene expression, since overexpression of the PTEN 3′ UTR was found to de-repress PTENP1 expression and inhibited DU145 proliferation ( Figure 4A ) (Poliseno et al., 2010) . These experiments will be replicated in Protocols 5 and 6. These results were also confirmed by experiments by Yu and colleagues showing that overexpression of either PTEN or PTENP1 suppressed renal cancer cell proliferation (Yu et al., 2014) . Further to this, the oncosuppressive properties of overexpressing PTENP1 3′ UTR have been reported in various cancer cells (Poliseno et al., 2010; Chen et al., 2015; Guo et al., 2015) .
Sampling ■ Experiment to be repeated a total of six times for a minimum power of 88%.
○ See 'Power calculations' section for details. ■ Experiment has 5 conditions:
○ Cohort 1: siGENOME non-targeting siRNA #2 (siLUC) transfected DU145 cells. Figure 1D ).
Confirmatory analysis plan
This replication attempt will perform the statistical analysis listed below.
■ Statistical Analysis: ○ Note: at the time of analysis, we will perform the Shapiro-Wilk test and generate a quantilequantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the planned comparisons using the Wilcoxon-Mann Whitney test. ○ One-way MANOVA of normalized PTEN or PTENP1 mRNA fold change in siLuc, 19b, or 20a siRNA transfected cells with the following planned comparisons using the ○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot. ■ Additional exploratory analysis: ○ The same analysis described above will be performed with 36B4 normalized values, which serves as an independent normalization control not included in the original analysis.
Known differences from the original study
The PTEN and PTENP1 mRNA levels will be normalized with an independent control (36B4) in addition to ACTIN. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. Transfection efficiency will be recorded for each replicate and any transfection that does not contain >90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency in the first attempt(s) does not obtain >90%, then any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. The sample purity (A 260/280 ratio) of the isolated RNA from each sample will be reported. The PTEN and PTENP1 mRNA levels will be normalized with an independent control (36B4). All the raw data, including the analysis files, will be uploaded to the project page on the Open Science Framework (OSF) (https://osf.io/yyqas) and made publically available.
Protocol 2: Cell growth assay following siRNA transfection
This experiment tests the effect of siRNA mediated depletion of PTEN, PTENP1, or both on the growth of DU145 cells. It is a replication of Figure 2F . Figure 2F ).
Sampling

Confirmatory analysis plan
This replication attempt will perform the following statistical analysis listed below.
■ Statistical Analysis:
○ Note: at the time of analysis, we will perform the Shapiro-Wilk test and generate a quantilequantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test. ○ Two-way ANOVA comparing Day 5 absorbance in siLuc, siPTEN, siPTENP1, or siPTEN/PTENP1 transfected cells with the following planned comparisons using the Bonferroni correction: 1. siLuc compared to siPTEN. 2. siLuc compared to siPTENP1. 3. siLuc compared to siPTEN/PTENP1. 4. siPTEN/PTENP1 compared to siPTEN. 5. siPTEN/PTENP1 compared to siPTENP1. ○ Two-way ANOVA comparing area under the curve (AUC) measurements (determined from day 0, 1, 2, 3, 4, and 5 for each replicate) from absorbance in siLuc, siPTEN, siPTENP1, or siPTEN/ PTENP1 transfected cells with the following planned comparisons using the Bonferroni correction. 1. siLuc compared to siPTEN. 2. siLuc compared to siPTENP1. 3. siLuc compared to siPTEN/PTENP1. 4. siPTEN/PTENP1 compared to siPTEN. 5. siPTEN/PTENP1 compared to siPTENP1. ■ Meta-analysis of effect sizes:
○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.
Known differences from the original study All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm its identity and will be sent for mycoplasma testing to ensure there is no contamination. Transfection efficiency will be recorded for each replicate and any transfection that does not contain >90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency in the first attempt(s) does not obtain >90%, then any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. All the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/yyqas) and made publically available. Figure 2G , left). ○ Graph of fold change PTENP1 mRNA expression relative to siLuc. (Compare to Figure 2G , right).
Confirmatory analysis plan
■ Statistical Analysis: ○ Note: at the time of analysis, we will perform the Shapiro-Wilk test and generate a quantilequantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the planned comparisons using the Wilcoxon-Mann Whitney test. ○ One-way MANOVA of PTEN and PTENP1 mRNA levels in siLuc, siPTEN, siPTENP1, or siPTEN/ PTENP1 siRNA transfected cells with the following planned comparisons using the ○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot. ■ Additional exploratory analysis: ○ The same analysis described above will be performed with 36B4 normalized values, which serves as an independent normalization control not included in the original analysis.
Known differences from the original study
Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. Transfection efficiency will be recorded for each replicate and any transfection that does not contain >90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency in the first attempt(s) does not obtain >90%, then any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. The sample purity (A 260/280 ratio) of the isolated RNA from each sample will be reported. The PTEN and PTENP1 mRNA levels will be normalized with an independent control (36B4). All the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/yyqas) and made publically available.
Protocol 4: Western blot of cells transfected with siRNA
This experiment utilizes western blot to assess the protein levels of PTEN after depletion of PTEN, PTENP1, or both. It is a replication of Figure 2H .
Sampling ■ Experiment to be repeated a total of five times for a minimum power of 80%. The original data are qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.
○ 
Confirmatory analysis plan
■ Statistical Analysis:
○ Note: at the time of analysis, we will perform the Shapiro-Wilk test and generate a quantilequantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test. ○ Two-way ANOVA of normalized PTEN levels in siLuc, siPTEN, siPTENP1, or siPTEN/PTENP1 siRNA transfected cells with the following planned comparisons using the Bonferroni correction: 1. siLuc compared to siPTEN. 2. siLuc compared to siPTENP1. 3. siLuc compared to siPTEN/PTENP1. 4. siPTEN/PTENP1 compared to siPTEN. 5. siPTEN/PTENP1 compared to siPTENP1. ■ Meta-analysis of effect sizes:
○ The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.
Known differences from the original study
The original study used 12 well plates seeded with 1.5 × 10 5 DU145 cells per well, which was increased 2.5× to account for the difference in cell surface area. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. Transfection efficiency will be recorded for each replicate and any transfection that does not contain >90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency in the first attempt (s) does not obtain >90%, then any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. Ponceau stained membranes will be used to assess completeness of transfer. All the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/yyqas) and made publically available.
Protocol 5: Quantitative PCR following PTEN 3′ UTR transfection
This experiment tests the effect of expressing the 3′ UTR of PTENP1 on mRNA expression levels of PTENP1. It is a replication of the left panel of Figure 4A . Procedure Note c All cells will be sent for mycoplasma testing and STR profiling. c DU145 cells grown in complete RPMI 1640: RPMI 1640 supplemented with 2 mM glutamine, 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin at 37˚C and 6% CO 2 .
Materials and reagents
1. Grow and prepare endotoxin-free plasmid constructs following manufacturer's instructions for an endotoxin-free plasmid maxiprep kit. a. pCMV (empty vector). b. pCMV/PTEN 3′ UTR. i. Sequence gene of interest in each plasmid and run whole plasmids on agarose gel to confirm vector integrity. 2. Seed 3.5 × 10 5 DU145 cells per dish in 6 cm dishes. Grow overnight. 3. Transfect with pCMV or pCMV/PTEN 3′ UTR plasmids using Effectene according to manufacturer's instructions and recommended DNA and reagent amounts. 4. 24 hr after transfection, extract total RNA from each cohort directly on the culture dish using TRI reagent and 1-bromo-3-chloropropane according to manufacturer's instructions. 5. Treat RNA with DNase I following manufacturer's instructions. 6. Reverse transcribe 1 μg RNA/sample into cDNA using first-strand cDNA synthesis kit with primers following manufacturer's instructions. a. Record RNA concentration and purity (A 280 /A 260 ). 7. Perform quantitative PCR reaction using the QuantiTect SYBR Green PCR kit: a. Use 2 μl of reverse transcription reaction per 20 μl real-time PCR reaction. b. Perform quantitative PCR for PTENP1, ACTIN, and 36B4. i. PTENP1 forward primer: 5′-TCAGAACATGGCATACACCAA-3′ ii. PTENP1 reverse primer: 5′-TGATGACGTCCGATTTTTCA-3′ iii. ACTIN forward primer: 5′-CATGTACGTTGCTATCCAGGC-3′ iv. ACTIN reverse primer: 5′-CTCCTTAATGTCACGCACGAT-3′ v. 36B4 forward primer: 5′-GTGTTCGACAATGGCAGCAT-3′ vi. 36B4 reverse primer: 5′-GACACCCTCCAGGAAGCGA-3′ c. 36B4 primer sequences reported in Fullwood et al. (2009) . d. Do not pre-treat with uracil-N-glycosylase. e. All reactions should be optimized and run in technical triplicate. 8. Using ACTIN as an internal standard, calculate the fold change in PTEN1P expression relative to pCMV expressing cells using the comparative Ct method. a. Additionally perform normalization using 36B4 as an internal standard (additional control). 9. Repeat independently two additional times.
Deliverables
■ Data to be collected:
○ Purity (A 260/280 ratio) and concentration of isolated total RNA from cells. ○ Raw data for all qPCR reactions. ○ Quantification of PTENP1 mRNA levels relative to ACTIN or 36B4. ○ Quantification of fold change PTENP1 mRNA levels relative to pCMV transfected cells. (Compare to Figure 4A , left panel).
Confirmatory analysis plan
■ Statistical Analysis:
○ Note: at the time of analysis, we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity.
If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test. ○ Unpaired two-tailed t-test of PTENP1 mRNA levels of pCMV transfected cells compared to pCMV/PTEN 3′ UTR transfected cells.
■ Meta-analysis of effect sizes: ○ Compute the effect sizes of each comparison, compare them against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot. ■ Additional exploratory analysis: ○ The same analysis described above will be performed with 36B4 normalized values, which serves as an independent normalization control not included in the original analysis.
Known differences from the original study
The PTENP1 mRNA levels will be normalized with an independent control (36B4) in addition to ACTIN. All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. The sample purity (A 260/280 ratio) of the isolated RNA from each sample will be reported. The PTENP1 mRNA levels will be normalized with an independent control (36B4). All the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/yyqas) and made publically available.
Protocol 6: Cell growth assay following PTEN 3′ UTR transfection
This experiment tests the effect of expressing the 3′ UTR of PTENP1 on cell growth. It is a replication of the right panel of Figure 4A . 
Materials and reagents
Confirmatory analysis plan
■ Statistical Analysis: ○ Note: at the time of analysis, we will perform the Shapiro-Wilk test and generate a quantilequantile plot to assess the normality of the data. We will also perform Levene's test to assess homoscedasticity. If the data appear skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test. ○ Unpaired two-tailed t-test of Day 5 absorbance of pCMV transfected cells compared to pCMV/ PTEN 3′ UTR transfected cells. ○ Unpaired two-tailed t-test of AUC measurements (determined from day 0, 1, 2, 3, 4, and 5 for each replicate) of pCMV transfected cells compared to pCMV/PTEN 3′ UTR transfected cells. ■ Meta-analysis of effect sizes:
Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. All the raw data, including the analysis files, will be uploaded to the project page on the OSF (https://osf.io/yyqas) and made publically available.
Power calculations
For additional details on power calculations, please see analysis scripts and associated files on the OSF: https://osf.io/cd2yq/
Protocol 1
Summary of original data estimated from graph reported in Figure 1D :
Test family
■ 2 tailed t test, Wilcoxon-Mann-Whitney test, Bonferroni's correction: alpha error = 0.0125.
'Power calculations' performed with G*Power software, version 3.1.7 (Faul et al., 2007) .
■ Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above. ■ Two-way ANOVA: Fixed effects, special, main effects and interactions: alpha error = 0.05. *6 samples per group will be used based on the siLuc to 20a PTEN comparison making the power 99.9%. †6 samples per group will be used based on the siLuc to 20a PTEN comparison making the power 91.6%.
○ Due to a lack of raw original data, we are unable to perform power calculations using a MANOVA. We are using a two-way ANOVA to estimate sample size.
'Power calculations' performed with G*Power software, version 3.1.7 (Faul et al., 2007) . ANOVA F test statistic and partial η 2 performed with R software, version 3.1.2 (R Development Core Team, 2014).
■ Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above. ■ 2 tailed t test, difference between two independent means, Bonferroni's correction: alpha error = 0.0125.
Protocol 2
Summary of original data estimated from graph reported in Figure 2F : ■ 2 tailed t test, difference between two independent means, Bonferroni's correction: alpha error = 0.01.
Day 5 values AUC values
Protocol 3
Summary of original data estimated from graph reported in Figure 2G :
Test family
■ 2 tailed t test, Wilcoxon-Mann-Whitney test, Bonferroni's correction: alpha error = 0.008333.
■ Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above. ■ Two-way ANOVA: Fixed effects, special, main effects and interactions: alpha error = 0.05. ○ Due to a lack of raw original data, we are unable to perform power calculations using a MANOVA. We are using a two-way ANOVA to estimate sample size.
■ Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.
■ 2 tailed t test, difference between two independent means, Bonferroni's correction: alpha error = 0.008333.
'Power calculations' performed with G*Power software, version 3.1.7 (Faul et al., 2007) . *5 samples per group will be used based on the siLuc to siPTENP1 PTEN comparison making the power 99.9%. †5 samples per group will be used based on the siLuc to siPTENP1 PTEN comparison making the power 95.1%. ‡5 samples per group will be used based on the siLuc to siPTENP1 PTEN comparison making the power 99.9%. §5 samples per group will be used based on the siLuc to siPTENP1 PTEN comparison making the power 99.6%. 
Protocol 4
Summary of original data reported in Figure 2H : The original data do not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.
Test family
■ Two-way ANOVA: Fixed effects, special, main effects and interactions: alpha error = 0.05.
2% variance:
15% variance:
28% variance:
40% variance:
■ 2 tailed t test, difference between two independent means, Bonferroni's correction: alpha error = 0.01.
'Power calculations' performed with G*Power software, version 3.1.7 (Faul et al., 2007 Continued on next page
